Brief: Quantum Genomics Announces Positive Study Results For Firibastat

Quantum Genomics SA

06/02/2019 17:04

Feb 6 (Reuters) - QUANTUM GENOMICS SA  ALQGC.PA :
    * ANNOUNCES THE PUBLICATION OF TWO SCIENTIFIC ARTICLES
CONFIRMING
THE EFFICACY OF FIRIBASTAT FOR HEART FAILURE
    * STUDY DEMONSTRATED THAT REPEATED ORAL ADMINISTRATION OF
FIRIBASTAT REDUCED CARDIAC DYSFUNCTION AFTER MYOCARDIAL
INFARCTION AS EFFECTIVELY AS LOSARTAN
    * HOWEVER, UNLIKE LOSARTAN, FIRIBASTAT DID NOT INDUCE
HYPOTENSION
OR INCREASE RISK OF DEGRADING RENAL FUNCTION
    * STUDY SHOWED THAT FIRIBASTAT ADMINISTERED ORALLY FOR FOUR
OR
EIGHT WEEKS TO MICE WITHIN 48 HOURS AFTER MYOCARDIAL INFARCTION
IS AT LEAST AS EFFECTIVE AS ENALAPRIL

Source text for Eikon:  ID:nGNX1rkPVd 
Further company coverage:  ALQGC.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))